This is a working overview of WADA, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-10 and is reviewed periodically as new material appears.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
=== Salt balance === Dermal macrophages facilitate skin homeostasis by regulating the skin's salt composition. For instance, an increase in salt concentration after a salt-heavy meal attracts dermal macrophages that express TonEBP, a transcriptional factor responding to osmotic pressure changes. This process triggers VEGF-C transcription, resulting in the growth of lymph capillaries and blood vessels dilation, regulating salt-sensitive hypertension by lowering the blood pressure. An increase in sodium ions concentration also facilitates the polymerisation of glycosaminoglycans, which helps the storage of sodium ions in the skin. A salt solution such as sodium chloride in the skin can trigger hypertonic stress, which acts as a stimulus for attracting macrophages. A higher salt concentration also causes macrophages activation. It induces the expression of pro-inflammatory genes such as CXCL-1, CCL2, and IL-1 and inhibits anti-inflammatory genes such as CCL18 and CCL22. Hence, the activation of dermal macrophages can be achieved by the local salt concentration, independent of the salt ingested. The expression of such genes could contribute to the skin's defence against parasitic infections.
=== Later medieval works === The Fisher King is a character in Chrétien's Perceval (1180) which is the first of a series of stories and texts on the subject of Perceval and the Grail. In his work, Chrétien did not say how the quester was related to this Fisher King. In later romances it is made clear, in the end, that he is the uncle of the quester. According to Eugène Vinaver, Chretien's work features two Maimed Kings. Parzival was written in 1210 by Wolfram von Eschenbach, thirty years after Perceval. Although a different work, it is strikingly similar to Perceval. The story revolves around the Grail Quest and once again the main character is Perceval (as Parzival). As in Perceval, the story has its protagonist fail to ask the healing question, which results in him Questing for years. However, Parzival differs from Perceval in three major ways. Firstly, the Fisher King is no longer nameless and is called Anfortas. Secondly, Eschenbach thoroughly describes the nature of the wound; it is a punishment for wooing a woman who is not meant for him (every Grail keeper is to marry the woman the Grail determines for him), and it causes him immense pain. Lastly, Parzival comes back to cure the Fisher King. Parzival, unlike its predecessor Perceval, has a definitive ending. The quester is the son of Herzeloyde, who is the sister of Anfortas.
Countries have differing standards for grading honey. In the US, honey grading is performed voluntarily based upon USDA standards. USDA offers inspection and grading "as on-line (in-plant) or lot inspection...upon application, on a fee-for-service basis." Honey is graded based upon a number of factors, including water content, flavor and aroma, absence of defects, and clarity. Honey is also classified by color, though it is not a factor in the grading scale. The USDA honey grade scale is:
Sources: en.wikipedia.org
Aromatic L-amino acid decarboxylase (AADC or AAAD), also known as DOPA decarboxylase (DDC), tryptophan decarboxylase, and 5-hydroxytryptophan decarboxylase, is a lyase enzyme (EC 4.1.1.28), located in region 7p12.2-p12.1.
Saddam's foreign minister Tariq Aziz later told PBS Frontline in 1996 that the Iraqi leadership was under "no illusion" about America's likely response to the Iraqi invasion: "She [Glaspie] didn't tell us anything strange. She didn't tell us in the sense that we concluded that the Americans will not retaliate. That was nonsense you see. It was nonsense to think that the Americans would not attack us." Then in a second 2000 interview with the same television program, Aziz said:There were no mixed signals. We should not forget that the whole period before August 2 witnessed a negative American policy towards Iraq. So it would be quite foolish to think that, if we go to Kuwait, then America would like that. Because the American tendency ... was to untie Iraq. So how could we imagine that such a step was going to be appreciated by the Americans? It looks foolish, you see, this is fiction. About the meeting with April Glaspie—it was a routine meeting...She didn't say anything extraordinary beyond what any professional diplomat would say without previous instructions from his government...what she said were routine, classical comments on what the president was asking her to convey to President Bush. He wanted her to carry a message to George Bush—not to receive a message through her from Washington.
== External links == ELISA at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "Introduction to ELISA Activity"—beginner walk-through of ELISA used for detecting HIV, including animations at the University of Arizona "ELISA Assay Principle" - An overview of the principle of an ELISA and tools for detecting analyties at Assay Genie
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.